Evidence map›Paper›PMID 38258127›Full record

ArticlePharmaceutics2024

Effects of H2-Receptor Antagonists on the Exposure of Dacomitinib.

Jian Liu, Swan Lin, Anthony Huynh, Weiwei Tan

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Jian LiuClinical Pharmacology, Pfizer Investment Co., Ltd., Beijing 100010, China.ORCID 0000-0002-9796-0176
Swan LinClinical Pharmacology, Global Product Development, Pfizer Inc., San Diego, CA 92121, USA.
Anthony HuynhSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, CA 92093, USA.
Weiwei TanClinical Pharmacology, Global Product Development, Pfizer Inc., San Diego, CA 92121, USA.
Pfizer (United States) · USPfizer (China) · CNUniversity of California San Diego · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dacomitinib is an irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor indicated for the treatment of patients with advanced non-small-cell lung cancer (NSCLC) and EGFR-activating mutations. Proton-pump inhibitors decreased dacomitinib exposure. This analysis summarizes the effect of Histamine-2 receptor antagonists (H2RAs) on dacomitinib exposure. A within-patient comparison of the steady-state trough concentrations (C

Indexed as

dacomitinibEGFR inhibitoroverall survivalpharmacokineticsprogression-free survivalproton-pump inhibitors

Identifiers

PMID38258127
PMCPMC10819565
OpenAlexW4390954299

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.